sitagliptiini

Sitagliptin is a medication used to treat type 2 diabetes. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. The active ingredient in sitagliptin is sitagliptin phosphate, which works by increasing the amount of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in the body. These hormones help to regulate blood sugar levels by stimulating the pancreas to produce more insulin and by reducing the amount of glucose released by the liver.

Sitagliptin is typically taken once daily, with or without food. It is available in tablet form and is usually prescribed as part of a combination therapy with other antidiabetic medications, such as metformin or sulfonylureas. The most common side effects of sitagliptin include nausea, diarrhea, and upper respiratory tract infections. These side effects are usually mild and transient.

Sitagliptin was approved by the U.S. Food and Drug Administration (FDA) in 2006 and by the European Medicines Agency (EMA) in 2007. It is marketed under the brand name Januvia and is available in generic form. Sitagliptin is generally well-tolerated and has been shown to be effective in improving glycemic control in patients with type 2 diabetes. However, as with any medication, it is important to use sitagliptin under the guidance of a healthcare professional and to follow the prescribed dosage and instructions.